English

Invent Medic Sweden - Q3 financial report

Report this content

The company’s first product Efemia was launched on the Swedish market on the 1st of October

First nine months (January – September 2018)

  • The company’s sales amounted to 0 (0) KSEK. 
  • Other operating income amounted to 17 (153) KSEK. 
  • Capitalised development expenses amounted to 428 (522) KSEK. 
  • Operating costs amounted to 7 048 (5 886) KSEK. 
  • Result before and after tax amounted to -6 604 (-5 211) KSEK. 
  • Result per share amounted to -0,68 (-0,61) SEK. 
  • Cash and cash equivalents at the end of the period amounted to 16 297 KSEK. 

Third quarter (July – September 2018) 

  • Other operating income amounted to 17 (153) KSEK. 
  • Capitalised development expenses amounted to 67 (170) KSEK. 
  • Operating costs amounted to 2 537 (2 076) KSEK. 
  • Result before and after tax amounted to -2 453 (-1 753) KSEK. 
  • Result per share amounted to -0,24 (-0,19) SEK.

CEO Karin Bryder summarises the quarter 

During the third quarter of 2018 we received the CE mark approval for Efemia continence support, our first product. We also focused on the preparations for the market launch of the product that was initiated after the end of the period. Efemia has been developed for several years, and we are happy to now be able to offer a unique solution that can change the everyday life for a large number of women. With the market launch, Invent Medic is starting a new  chapter with the Efemia launch in the Nordics and then the rest of Europe followed by the USA as the main priority. At present, the product is available for businesses and individuals through Arcamea’s online store, and we are also in discussions with potential distributors and pharmacies to make the product visible to even more women and possible to purchase through retail stores.

For information on Invent Medic Sweden AB, please contact: 
Karin Bryder, CEO
Phone: 0723 81 17 10
E-post: info@inventmedic.com

Invent Medic Sweden AB, Company registration number 556682-1046, has developed a medical device, Efemia, for non-surgical relief of female stress urinary incontinence. The inventors behind the product, Jan Clarén and Lars-Olof Henriksson, have been involved in the development and performance of the surgical method TVT, which is now known as the Golden Standard for surgical treatment of female stress incontinence. The product is based on the same scientific basis and has similar mechanism of action as the surgical method but is based on a non-surgical support and is designed so that the woman can use the product when needed. This product has the potential to satisfy a major medical need and could thus have a significant market value. Invent medic's vision is to offer new and innovative medical devices and treatment methods to women with the goal of improving their health and quality of life. The offer shall include safe, effective and safe products and treatment methods that should be easy to use and which will provide health economic benefits to society. Invent Medic Sweden AB is listed on Aktietorget. Ticker is IMS and the share's ISIN code is SE0007603402. For more information see www.inventmedic.com and www.spotlightstockmarket.com.

Subscribe

Documents & Links